cpi 1189 has been researched along with hydroxyl radical in 1 studies
| Studies (cpi 1189) | Trials (cpi 1189) | Recent Studies (post-2010) (cpi 1189) | Studies (hydroxyl radical) | Trials (hydroxyl radical) | Recent Studies (post-2010) (hydroxyl radical) |
|---|---|---|---|---|---|
| 8 | 1 | 3 | 10,147 | 26 | 3,657 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arendash, GW; Bjugstad, KB; Flitter, WD; Garland, WA; Kirstein, CL; Philpot, RM | 1 |
1 other study(ies) available for cpi 1189 and hydroxyl radical
| Article | Year |
|---|---|
CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex.
Topics: Administration, Oral; AIDS Dementia Complex; Animals; Antioxidants; Apoptosis; Astrocytes; Basal Ganglia; Blood-Brain Barrier; Butanes; Corpus Callosum; Depression, Chemical; Disease Models, Animal; Drug Evaluation, Preclinical; Glial Fibrillary Acidic Protein; Gliosis; Hydroxyl Radical; Immunoglobulin G; Injections, Intraventricular; Lipid Peroxidation; Male; Neocortex; Neuroprotective Agents; Nitrogen Oxides; Oxidative Stress; Rats; Rats, Sprague-Dawley; Salicylates; Septum Pellucidum; Thiobarbituric Acid Reactive Substances; Tumor Necrosis Factor-alpha | 2000 |